yemenjmedYemen Journal of MedicinecoVolume 3 Issue 1MultidisciplinaryEnglishJanuary-April 2024NNY20240511ArticleGalectin-3 expression by thyroid neoplasms in a center in southwest NigeriaEnglishY3035Ademola IdowuSoremekun1EnglishNOlaejirinde OlaniyiOlaofe1EnglishYAkinwumi OluwoleKomolafe1EnglishY10.32677/yjm.v3i1.4452Background: Galectin-3 (GAL-3), which is known to be expressed in certain normal tissues and is implicated in tumor progression and metastasis, serves as a valuable marker for distinguishing malignant thyroid lesions from benign thyroid lesions. This study aimed to assess the clinical and histopathological features of thyroid neoplasms at OAUTHC Ile Ife utilizing GAL-3 immunohistochemistry and to compare these findings with those of studies conducted in other regions of the world. Materials and Methods: Histology slides from 56 patients with thyroid neoplasms spanning a 20-year period were subjected to immunohistochemical staining with monoclonal antibodies against GAL-3. Evaluation was based on the 2022 World Health Organization Classification of Thyroid Neoplasms, categorizing marker expression as follows: 1+ (10–25% stained cells), 2+ (26–50% stained cells), 3+ (51–75% stained cells), and 4+ (>75% stained cells). Negative staining indicated no staining, while localized staining (focal) represented 50% of cells stained (3+ or 4+). Results: A total of 56 patients with neoplastic thyroid disease were studied, including 15 males and 41 females. Among the 16 benign neoplastic lesions, four (25.0%) exhibited focal GAL-3 expression, while 12 (75.0%) showed no expression. Among the forty malignant neoplastic lesions, five (12.5%) tested negative for the GAL-3 immunomarker, while 35 (87.5%) demonstrated positive expression to varying degrees. Among the positive malignant lesions, two (5.0%) displayed focal GAL-3 expression, while 33 (82.5%) exhibited diffuse staining of tumor cells. The diffuse and strong expression of GAL-3 was significantly greater in malignant thyroid neoplasms than in benign neoplasms (pEnglishAntibody, Galectin-3, Immunohistochemistry, Neoplasm, Thyroidhttps://yemenjmed.com/admin/abstract?id=95References16191.and;nbsp; and;nbsp;Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015;139(1):67and;ndash;82.2.and;nbsp; and;nbsp; Razand;nbsp; A, Carmi P, Raz T, et al. Molecular cloning and chromosomal mapping of a human galactoside-binding protein. Cancer Res. 1991;51(8):2173and;ndash;2178.3.and;nbsp; and;nbsp; Pernick N. Galectin 3 [Internet]. Pathology outlines. 2013 [cited 2017 May 1]. Available from: http//www.pathologyoutlines.com/stains and molecular markers/galectin 3.4.and;nbsp; and;nbsp; Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008;132(3):359and;ndash;372.5.and;nbsp; and;nbsp; CancerResearchUK. Thyroid cancer statistics [Internet]. Cancer Research UK. 2013 [cited 2016 Sep 22]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer.6.and;nbsp; and;nbsp; Ariyibi O, Duduyemi B. Histopathological Patterns of Thyroid Neoplasms in Ibadan Nigeria: A Twenty Year Retrospective Study. Int J Trop Dis Heal. 2013;3(2):148and;ndash;156.7.and;nbsp; and;nbsp; Olatoke S, Ajape A, Rahman G, et al. Thyroid Malignancies in Ilorin, Nigeria: A Clinico-pathological Review. J Surg Surg Sci. 2010;1(4):108and;ndash;112.8.and;nbsp; and;nbsp; Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2002;26(11):1508and;ndash;1514.9.and;nbsp; and;nbsp; Franc B, De La Salmoniand;egrave;re P, Lange F, et al. Interobserver and Intraobserver Reproducibility in the Histopathology of Follicular Thyroid Carcinoma. Hum Pathol. 2003;34(11):1092and;ndash;1100.10.and;nbsp; Nechifor-Boilǎ A, Cǎtanǎ R, Loghin A, et al. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 2014;55(1):49and;ndash;56.11.and;nbsp; Adeniyi KA, Anjorin AS, Ogunsulire IA. Histological patterns of thyroid diseases in a Nigerian Population. Nig. Qt. J. Hosp. Med. J. 1998;8(4):241-244.12.and;nbsp; Tsegaye B, Ergete W. Histopathologic pattern of thyroid disease. East Afr Med J. 2003;80:525and;ndash;528.13.and;nbsp; Der E, Quayson S, Clegg-Lamptey J, et al. Thyroid Disorders in Accra, Ghana: A Retrospective Histopathological Study at the Korle-Bu Teaching Hospital. J Med Biomed Sci. 2013;2(1):1and;ndash;7.14.and;nbsp; Ijomone E, Duduyemi B, Udoye E, et al. Histopathological review of thyroid diseases in southern Nigeria- a ten year retrospective study.12. J Med Med Sci 2014;5(6)127-132. 2014;5(6):127and;ndash;32.15.and;nbsp; La Vecchia C, Ron E, Franceschi S, et al. A pooled analysis of case‒control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control. 1999;10(2):157and;ndash;166.16.and;nbsp; Memon A, Darif M, Al-Saleh K, et al. Epidemiology of reproductive and hormonal factors in thyroid cancer: Evidence from a case‒control study in the Middle East. Int J Cancer. 2002;97(1):82and;ndash;89.17.and;nbsp; Lawal O, Agbakwuru A, Olayinka OS, et al. Thyroid malignancy in endemic nodular goitres: prevelence, pattern and treatment. Eur J Surg Oncol. 2001;27:157-161.18.and;nbsp; Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18(1):48and;ndash;57.19.and;nbsp; Scognamiglio T, Hyjek E, Kao J et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126(5):700and;ndash;70820.and;nbsp; Park YJ, Kwak SH, Kim DC, et al. Diagnostic Value of Galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin d1 and p27kip1 in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007;22:621-628.21.and;nbsp; Saleh HA, Jin B, Barnwell J, et al. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9.22.and;nbsp; Xu XC, El-Naggar AK, Lotan R. Differential Expression of Galectin-1 and Galectin-3 in Thyroid Tumours. Potential Diagnostic Implications. Am J Pathol. 1995;147(3):815-822.23.and;nbsp; Bartolazzi A, Gasbarri A, Papotti M,and;nbsp; et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644and;ndash;1650.